FDA panel against higher dose of Lilly-Incyte arthritis drug
(Reuters) - An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
from Reuters: Health News https://reut.rs/2qTECQk
http://bit.ly/2zwRqiM